Ticker
AKYA

Price
13.92
Stock movement up
+0.68 (5.14%)
Company name
Akoya Biosciences Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Medical Instruments & Supplies
Markedsverdi
523.25M
Ent verdi
509.89M
Pris/omsetning
32.38
Pris/bok
4.91
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-2.61%
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-18.41%
3 års avkastning
-
5 års avkastning
-
10 års avkastning
-
Sist oppdatert: 2022-08-25

UTBYTTE

AKYA betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning32.38
Pris til bok4.91
EV i forhold til salg31.56

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall37.59M
EPS (TTM)-0.94
FCF per aksje (TTM)-1.47

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)16.16M
Bruttofortjeneste (TTM)-20.43M
Driftsinntekter (TTM)-33.90M
Netto inntekt (TTM)-34.85M
EPS (TTM)-0.94
EPS (1 år fremover)-1.14

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-126.46%
Driftsmargin (TTM)-209.78%
Fortjenestemargin (TTM)-215.70%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter93.94M
Netto fordringer11.31M
Samlede omløpsmidler126.47M
Goodwill18.26M
Immaterielle eiendeler20.96M
Eiendom, anlegg og utstyr0.00
Sum eiendeler187.13M
Leverandørgjeld11.52M
Kortsiktig/nåværende langsiktig gjeld43.72M
Sum kortsiktig gjeld31.74M
Sum gjeld80.58M
Aksjonærenes egenkapital106.55M
Netto varige driftsmidler67.33M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-49.60M
Kapitalutgifter (TTM)5.33M
Fri kontantstrøm (TTM)-54.92M
Utbetalt utbytte (TTM)1.44M

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-32.71%
Avkastning på eiendeler-18.63%
Avkastning på investert kapital-31.76%
Kontantavkastning på investert kapital-50.05%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning13.27
Daglig høy14.06
Daglig lav13.03
Daglig volum130K
Tidenes høyeste26.05
1 år analytikerestimat18.75
Beta-
EPS (TTM)-0.94
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon7 Nov 2022

Nedsidepotensial

Loading...
Nedsidepotensial-data
AKYAS&P500
Nåværende prisfall fra toppnotering-46.56%-12.18%
Høyeste prisfall-67.83%-56.47%
Dato for høyeste fall9 May 20229 Mar 2009
Gj.snittlig fall fra topp-45.24%-11.38%
Gj.snittlig tid til ny topp345 days12 days
Maks tid til ny topp344 days1805 days
SELSKAPSOPPLYSNINGER
AKYA (Akoya Biosciences Inc) company logo
Markedsverdi
523.25M
Markedsverdi kategori
Small-cap
Beskrivelse
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Ansatte
319
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
USA
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
MARLBOROUGH, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in four upcoming inv...
31. august 2022
In this article, we discuss 10 rebounding small cap stocks to buy now. If you want to see the top stocks in this category, check out 5 Rebounding Small-Cap Stocks to Buy Now. Carter Worth, the CEO of ...
11. august 2022
Thank you for standing by, and welcome to the Akoya Biosciences second quarter 2022 earnings conference call. On the call today, we have Brian McKelligon, chief executive officer; and Joe Driscoll, c...
9. august 2022
Akoya (AKYA) delivered earnings and revenue surprises of -38.24% and 5.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
8. august 2022
Q2 2022 revenue $17.9 million, 37% y/y growthRaising FY 2022 revenue guidance range to $71-74 million MARLBOROUGH, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Ako...
8. august 2022
MARLBOROUGH, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in two upcoming inve...
27. juli 2022
MARLBOROUGH, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the sec...
12. juli 2022
Akoya Biosciences AKYA is a life sciences company that provides spatial biology solutions focused on transforming discovery and clinical research. In this daily bar chart of AKYA, below, we can see b...
1. juli 2022
If you want to know who really controls Akoya Biosciences, Inc. ( NASDAQ:AKYA ), then you'll have to look at the makeup...
29. juni 2022
The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2 targeted on...
28. juni 2022
Neste side